News
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain
Abbas Hussain zum neuen Chief Executive Officer von Vifor Pharma ernannt
Regulatory News:
Abbas Hussain (56, britischer Staatsbürger) verfügt über eine mehr als 30-jährige erfolgreiche und internationale Karriere als Führungskraft im Gesundheitssektor. Von 2008 bis
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
Regulatory News:
Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in
93rd Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19
93. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 93. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt. Angesichts der anhaltenden
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21)
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
Regulatory News:
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/
Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
Regulatory News:
Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much
Vifor Pharma schliesst 2020 mit starkem Geschäftsergebnis und EBITDA-Anstieg um über 29% auf 576 Millionen Schweizer Franken ab1
Regulatory News:
Die Vifor Pharma Gruppe weist auch für 2020 trotz des durch COVID-19 erschwerten Patientenzugangs und den Folgen des gegenüber dem US-Dollar deutlich stärkeren Schweizer Franken
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Regulatory News:
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
Regulatory News:
Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Regulatory News:
Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201108005065/en/
Vifor Pharma and Angion Biomedica Corp. (Angion)
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005955/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
BB Biotech: Ein drittes Quartal zum Abhaken
BB Biotech (WKN: A0NFN3) legte heute seinen Quartalsbericht vor und informierte zugleich über „erhöhte Übernahmeaktivitäten“ im Pharmasektor, aus denen die Investmentgesellschaft selbst Kapital
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/
Vifor Pharma and Cara Therapeutics, Inc
Santhera: Endgültiger Studienstopp von DMD-Medikament
Dämpfer für Santhera Pharmaceuticals (WKN: A0LCUK): Die Schweizer Biotechschmiede stellt die zulassungsrelevante Phase-3-Studie mit Puldysa bei Patienten mit Duchenne-Muskeldystrophie (DMD) ein. Die
Vifor Pharma announces outcome of AFFIRM-AHF topline data
Regulatory News:
Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and
Vifor Pharma Group Announces Successful Sale of OM Pharma
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal